|
|
|
| home > white papers > Cleaning Validation: What do you need to consider to ensure a successful outcome? - RSSL |
|
|
 WHITE PAPERS |
|
RSSL
|
+44 (0)118 918 4024
|
|
http://www.rssl.com
|
|
University of Reading, Whiteknights Rd, Reading, West Berkshire RG6 6LA
|
|
|
Cleaning Validation: What do you need to consider to ensure a successful outcome?
|
|
Cross contamination must be avoided in the Pharmaceutical industry at
all costs and successful cleaning validation ensures that patients are
not put at risk due to cross contamination.
The process can be
divided into a number of sections each of which must be fully understood
and areas of concern addressed to ensure a successful outcome across
the entire process. This spans both the manufacturing and subsequent
analytical and microbological support.
The data used to confirm a
positive/successful cleaning validation is underpinned by the results
of validated analytical methods. It is essential that these results are
truly representative as patient safety is based upon the absence of
equipment residues.
So what are those areas of concern, what
affects your ability to get a successful outcome and what do you need to
consider when carrying out a Cleaning Validation exercise?
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Agilent Joins AMBIC to Advance Biomanufacturing
SANTA CLARA, Calif., April 04, 2022 – Agilent Technologies Inc.
(NYSE: A) announced today that it has become a member of the Advanced
Mammalian Biomanufacturing Innovation Center (AMBIC). Joining AMBIC
demonstrates the company’s commitment to partnering to support the
provision of the next generation of analytical tools and comprehensive
solutions needed by academic, pharmaceutical, and clinical researchers.
More info >> |
|
 |
White Papers |
 |
|
Achieve full compliance with tamper-verification pharma solutions
UPM Raflatac
UPM Raflatac has developed a range of pharmaceutical labelling products to support compliance with the Falsified Medicines Directive on packaging for prescription drugs and high-risk, over-the-counter medicines. Few solutions offer the same ease of adoption for meeting the February 2019 deadline.
More info >> |
|
|
|
